Associate Professor

Tel: 0551-65595117

Email: wuhong@hmfl.ac.cn

Education Background

2013/09-2016/06 Univerisity of Scinece and Technology of China, Biology department,Ph.D

2008/09-2011/06 Anhui University,Biology department,Master

2004/09-2008/06 Anhui Agriculture University, Biology Department,B.S

Research Experience

2016/07-now, Postdoctoral Associate, High Magnetic Field Laboratory, Chinese Academy of Sciences

2011/08-2013/09, Technician, High Magnetic Field Laboratory, Chinese Academy of Sciences

Publications

1. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu.* Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 2017, 8(11): 18359-18372. doi: 10.18632/oncotarget.15443
2. Hong Wu#, Aoli Wang#, Ziping Q#i, Xixiang Li#, Cheng Chen#, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 2016, 30(10): 2112-2116.
3. Aoli Wang#, Hong Wu #, Cheng Chen#, Chen Hu#, Ziping Qi#, Wenchao Wang, Kailin Yu, Xiaochuan Liu, Fengming Zou, Zheng Zhao, Jiaxin Wu, Juan Liu, Feiyang Liu, Wang Li, Richard M. Stone, Ilene A. Galinksy, James D. Griffin4, Shanchun Zhang, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu *. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget 2016, 7(20): 29131-42.
4. Hong Wu #, Aoli Wang#, Wei Zhang#, Beilei Wang#, Cheng Chen#,Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu*, Liang Chen*,Liu Qingsong*. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget 2015, 6(31): 31313-22.
5. Hong Wu #, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Yongfei Chen#, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*, Liu Qingsong*. Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia. Leukemia 2016, 30(1):173-81. 
6. Hong Wu #, Hu Chen#, Wang Aoli#, E L Weisberg#, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin,Liu Jing* and Liu Qingsong*. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 2016, 30(3): 754-7.
7. Hong Wu #, Wenchao Wang#, Feiyang Liu#, Ellen E. Weisberg#, Bei Tian, Yongfei Chen, Binhua Li, Aoli Wang , Beilei Wang, Zheng Zhao, Douglas W. McMillin, Chen Hu, Hong Li, Jinhua Wang, Yanke Liang, Sara J. Buhrlage, Junting Liang, Jing Liu, Guang Yang, Jennifer R. Brown, Steven P. Treon, Constantine S. Mitsiades, James Griffin, Qingsong Liu*, Nathanael S. Gray*. Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. ACS Chem. Biol. 2014, 9(5): 1086-91.
8. Zheng Zhao, Hong Wu , Li Wang, Yi Liu, Stefan Knapp, Qingsong Liu*, Nathanael S. Gray*. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery. ACS Chem. Biol. 2014, 9(6): 1230-41.
9. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen#, Wenchao Wang, Chen Hu, Hong Wu , Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*,Liu Qingsong*. Discovery of R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)iperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem. 2015, 58(24): 9625-38.
10. Kim HG#, Tan L#, Weisberg EL#, Liu F#, Canning P, Choi HG, Ezell SA, Hong Wu , Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q*, Lee SW*, Gray NS*. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem. Biol. 2013, 8(10): 2145-50.
11. Feiyang Liu#, Xin Zhang#, Ellen Weisberg#, Sen Chen#, Wooyoung Hur, Hong Wu , Zheng Zhao, Wenchao Wang, Mao Mao, Changmeng Cai, Nicholas I. Simon, Takaomi Sanda, Jinhua Wang, A. Thomas Look, James D. Griffin, Steve Balk*, Qingsong Liu*, Nathanael S. Gray*. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem. Biol. 2013, 8(7): 1423-1428.

Patents

1. "Triciribine and its metabolite is sensitive to FLT3-ITD dependent AML!", Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong;Wang Wenchao; Chen Cheng;Hu Chen;Li Binhua; Ziping Qi; Yu Kailin;Wang Li. (2015)
PCT/CN2015/092600  
2. "A new type of FLT3 kinase inhibitors and its application!",Liu, Qingsong; Liu Jing;Li Binhua;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Yu Kailin;Wang Beilei; Wang Li. (2015)
PCT/CN2015/090306 
3. "FLT3 kinase new inhibitors and its application!",  Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Wu Jiaxin; Liu Juan;Yu Kailin; Wang Wei; Wang Li; Wang Beilei. (2015)PCT/CN2015/086318 
4. "A674563 is sensitive to FLT3-ITD dependent AML!",  Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong; Chen Cheng; Hu Chen; Wang Wenchao; Liu Xiaochuan; Yu Kailin; Zhao Zheng; Wu Jiaxin; Liu Juan; Wang Li; Wang Beilei. (2015) PCT/CN2015/083717 
5. "New class of PI3K's kinase inhibitors!", Liu, Qingsong; Liu Jing;Zhang Xin;Liang Xiaofei;Liu Xiaochuan;Liu Juanjuan; Chen Cheng;Zhao Zheng;Wang Aoli; Wang Wenchao;Wu Hong; Wang Beilei; Wang Li. (2015) PCT/CN2015/081240 
6. "New application of Ibrutinib", Liu, Qingsong; Liu Jing; Wang Beilei; Wang Aoli; Wu Hong; Hu Chen; Wang Wenchao; Chen Cheng; Wang Li; Li Xixiang; Li Xiaoxiang; Xu Ziao.(2015) PCT/CN2015/081051
7. "New class of Bruton's tyrosine kinase inhibitors", Liu, Qingsong; Liu Jing; Chen Yongfei; Wu Hong; Wang Aoli; Wang Beilei; Hu Chen; Wang Wenchao; Chen Cheng.(2015) PCT/CN2015/071594 

1. 发明名称：一种新型布鲁顿酪氨酸激酶不可逆抑制剂
发明人：刘静， 刘青松， 梁前茅，陈永飞，陈程，王傲莉，吴宏，余凯琳，王伟，胡晨，王文超，亓爽，王蓓蕾，王黎
专利受理号：201610084082.1
2. 发明名称：一类新型的 EGFR 野生型和突变型的激酶抑制剂
发明人： 刘青松， 刘静， 李希祥， 王傲莉，吴宏，余凯琳，胡晨，王文超，陈程，邹凤鸣，齐紫平，王黎，王蓓蕾
专利受理号：201511030721.8
3. 发明名称：一种新型 EGFR 和 ALK 激酶的双重抑制剂
发明人： 刘静， 刘青松， 江桃山，王傲莉， 吴佳昕，吴宏，齐紫平，陈永飞，邹凤鸣，王文超，赵铮，王黎，王蓓蕾
专利受理号：201510946305.6

4. 发明名称：曲西立滨（Triciribine）及相关代谢产物对FLT3突变的急性白血病的应用
发明人：刘青松， 刘静， 王傲莉， 吴宏， 王文超，陈程，胡晨，李滨华，齐紫平，余凯琳，王黎
专利受理号：201510665488.4
5. 发明名称：一类新型的FLT3激酶抑制剂及其用途
发明人：刘青松， 刘静， 李滨华, 王傲莉，吴宏，陈程，王文超，胡晨，赵铮，余凯琳，王蓓蕾，王黎
专利受理号：201510608850.4
6. 发明名称：FLT3激酶的新型抑制剂及其用途
发明人：刘青松，刘静，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾
专利受理号：201510547224.9
7. 发明名称：A674563在携带FLT3突变型基因的急性白血病中的新用途
发明人：刘青松， 刘静， 王傲莉，吴宏，陈程，胡晨，王文超，刘晓川，余凯琳，赵铮，吴佳昕，刘娟，王黎，王蓓蕾
专利受理号：201510262944.0
8. 发明名称：FLT3激酶的新型抑制剂及其用途
发明人：刘静，刘青松，李希祥，王傲莉，吴宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾
专利受理号：201510028177.7
9. 发明名称：一种新型的 PI3K 激酶抑制剂
发明人：刘青松，刘静，张欣，梁小飞，刘晓川，刘娟娟，陈程，赵铮，王傲莉，王文超，吴宏，王蓓蕾，王黎
专利受理号：201410821908.9
10. 发明名称：一种新型结构的激酶抑制剂
发明人：刘青松，刘静，王强，刘飞扬，王蓓蕾，王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎
专利受理号：201410757626.7
11. 发明名称：依鲁替尼对FLT3-ITD突变的急性白血病的应用
 发明人：刘青松，刘静，吴宏，胡晨，王傲莉，王文超，陈程，李希祥，赵铮，王黎，王蓓蕾
 专利受理号：201410598948.1
12. 发明名称：依鲁替尼的新用途
 发明人：刘青松，刘静，王蓓蕾，王傲莉，吴宏，胡晨，王文超，陈程，王黎，李希祥
 专利受理号：201410258423.3